// App-Quantinova.ai

P467 : Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis

Researchers

Presenter

  • J. Pans

Principal Investigators

  • D.T. Rubin

  • S. Vermeire

  • J.O. Lindsay

  • B.E. Sands

  • C. Su

  • G. Friedman

  • H. Zhang

  • C. Kayhan

  • A. Manuchehri

  • P. Healey

Medical Centers

  • Hospital Clinic Barcelona, Barcelona, Spain

  • University of Chicago, Inflammatory Bowel Disease Center, Chicago, United States

  • Department of Gastroenterology , Univ. Hospitals Leuven, Leuven, Belgium

  • Institute of Dentistry, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

  • Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, United States

  • Pfizer Inc., Collegeville, United States

  • Pfizer Inc., Tadworth, United Kingdom

  • Pfizer Groton CT United States

Locations

  • Spain

  • United States

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT01458574

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved